GlassScriptPhysician profile
Gamdur S Brar
NPI 1154308484
$613.21
in general payments reported to CMS, 2019-2025
12 companies · $103 in 2025
The $103 reported for 2025 was more than what a typical Neonatal-Perinatal Medicine provider received nationally (typical 2025 total: $77.90).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $137 · 2020: $33.33 · 2021: $77.82 · 2022: $99.90 · 2023: $70.27 · 2024: $91.38 · 2025: $103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $265.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $120.61 | 2019-2023 | |
| Glaxosmithkline, LLC. | $99.08 | 2021-2025 | Bexsero, Rotarix |
| Cranial Technologies, INC | $97.81 | 2020-2025 | Doc Band |
| Sobi, INC | $70.66 | 2019 | |
| Verrica Pharmaceuticals INC. | $47.32 | 2024 | Ycanth |
| Sanofi Pasteur INC. | $40.96 | 2025 | |
| Merck Sharp & Dohme LLC | $30.49 | 2023 | Vaxneuvance, Vaxelis |
| Kowa Pharmaceuticals America, INC. | $24.27 | 2024 | Zoryve |
| Astrazeneca Pharmaceuticals LP | $23.63 | 2023 | Flumist Quadrivalent |
| Ultragenyx Pharmaceutical INC. | $21.06 | 2022 | |
| Hologic Sales and Service, LLC | $19.29 | 2019 | |
| Seqirus USA INC | $18.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gamdur Brar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.